Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan.
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.
Am Soc Clin Oncol Educ Book. 2023 May;43:e389810. doi: 10.1200/EDBK_389810.
Management of oral cavity squamous cell carcinoma (OSCC) involves a multidisciplinary team approach. Surgery is ideally the primary treatment option for nonmetastatic OSCC, and less invasive curative surgical approaches are preferred in early-stage disease to minimize surgical-related morbidity. For patients at high risk of recurrence, adjuvant treatment using radiation therapy or chemoradiation is often used. Systemic therapy may also be used in the neoadjuvant setting (for advanced-stage disease with the intent of mandibular preservation) or in the palliative setting (for nonsalvageable locoregional recurrence and/or distant metastases). Patient involvement in treatment decision is the key for patient-driven management, particularly in clinical situation with poor prognosis, for example, early postoperative recurrence before planned adjuvant therapy.
口腔鳞状细胞癌（OSCC）的治疗需要多学科团队合作。对于非转移性 OSCC，手术是理想的主要治疗选择，在早期疾病中，应优先采用微创的根治性手术方法，以最大限度地减少与手术相关的发病率。对于复发风险高的患者，通常使用辅助治疗，包括放疗或放化疗。在新辅助治疗（用于有保留下颌意愿的晚期疾病）或姑息治疗（用于无法挽救的局部区域复发和/或远处转移）中也可能使用全身治疗。患者参与治疗决策是患者驱动管理的关键，特别是在预后较差的临床情况下，例如计划辅助治疗前的早期术后复发。
